by San Rocco Therapeutics | May 19, 2026 | News
San Rocco Therapeutics Unveils Promising “MiNiRoLu” Gene Therapy Data at ASGCT According to the company, the SRT8 “MiNiRoLu” vector demonstrated approximately 30% higher functional titer, 35% greater transduction efficiency, and roughly 40% higher β-globin expression...
by San Rocco Therapeutics | Apr 30, 2026 | News
SRT announces their Next-Generation Gene Therapy for Hemoglobin Disorders San Rocco Therapeutics (SRT) today announced two abstracts at the upcoming 2026 ASGCT Annual Meeting highlighting its gene therapy platform, MiNiRoLu (SRT8-T87Q), and a companion diagnostic for...
by San Rocco Therapeutics | Apr 29, 2026 | News
SRT at ASGCT | Abstract 3507 3507 A lentiviral vector with enhanced titer and T87Q β-globin expression for treatment of severe β-hemoglobin disorders INTRODUCTIONSickle cell disease (SCD) and β-thalassemia are caused by defect or deficiency in adult β-globin....
by San Rocco Therapeutics | Apr 29, 2026 | News
SRT at ASGCT | Abstract 465 465 A RT-qPCR assay for precise detection and absolute quantification of the T87Q β-globin variant in erythroid progeny of lentivirus transduced human CD34+ cells INTRODUCTIONLentiviral vectors (LVV) encoding for erythroid-specific...
by San Rocco Therapeutics | Apr 10, 2026 | News
Gene and Cell Therapy Spotlighted in Resurrection LA Premiere May 1–7 as San Rocco Therapeutics Advances Toward a Cure San Rocco Productions announces the upcoming premiere of Resurrection, a feature film inspired by the real-world scientific and medical journey to...
